Aboriginal and Prisoner HCV Drug Coverage for HOLKIRA PAK™

On September 11th we were notified that AbbVie's new interferon-free hepatitis C treatment for genotype 1, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonovir and dasabuvir [±ribavirin]), is now formally listed by the Non-Insured Health Benefit Program (NIHB) and Correctional Services Canada (CSC). Both have listed HOLKIRA PAK™ in accordance with the Common Drug Review’s recommendations: liver fibrosis stage of ≥2, and treatment should be initiated by physic

Updated: HepCBC Patient Group Submissions to CADTH and BC Pharmacare

To view all submissions (2011 to present) HepCBC has made to either CADTH (to determine if drug should be allowed for sale in Canada for a specific purpose) and BC Pharmacare (to determine if drug should be covered/purchase reimbursed by Pharmacare) please see this updated link: http://hepcbc.ca/patient-group-submissions-bc-pharmacare-cadth/


What a Christmas Present! On December 23, 2014, Health Canada approved AbbVie's new interferon-free hepatitis C combo! HOLKIRA™ PAK (known in the USA as VIEKIRA™ PAK) has an overall 97% success rate for genotype 1 patients in research trials. All patients, even those with compensated cirrhosis, take it for only 12 weeks EXCEPT genotype 1a cirrhotic patients who have had a previous null response to pegylated interferon (pegIFN) and ribavirin, who must take

URGENT REQUEST for patient input into INTERFERON-FREE HCV 3-drug combo by AbbVie

We've been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE 3-drug combo ombitasvir (ABT-267), paritaprevir (ABT-450)+ritonavir, and dasubuvir (ABT-333) which was developed for Chronic Hepatitis C by pharmaceutical company, AbbVie. We urgently request input from individual HCV+ people with any genotype (both those who have and have not tried this drug combination). For background info see http://hepcbc.ca/contribute-to-abbvie-3d-su